Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CD55 anticorps (FITC)

CD55 Reactivité: Humain WB, FACS, IHC (fro) Hôte: Souris Monoclonal 4A143-30 FITC
N° du produit ABIN2144643
  • Antigène Voir toutes CD55 Anticorps
    CD55 (Complement Decay-Accelerating Factor (CD55))
    Reactivité
    • 116
    • 36
    • 7
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    Humain
    Hôte
    • 73
    • 69
    • 6
    • 6
    • 4
    • 1
    • 1
    Souris
    Clonalité
    • 89
    • 69
    • 2
    Monoclonal
    Conjugué
    • 74
    • 18
    • 16
    • 12
    • 5
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp CD55 est conjugé à/à la FITC
    Application
    • 98
    • 82
    • 47
    • 39
    • 33
    • 25
    • 16
    • 15
    • 14
    • 13
    • 9
    • 4
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Attributs du produit
    4A143-30 reacts with CD55, a 70 kDa GPI anchored single chain glycoprotein, referred to as decay accelerating factor (DAF). CD55 is widely expressed on hematopoietic cells including erythrocytes and NK cells, as well as on some non-hematopoietic cells. DAF protects cells from damage by autologous complement by preventing the amplification steps of the complement components. A defective PIG-A gene can lead to a deficiency of GPI -liked proteins such as CD55 and an acquired hemolytic anemia. This biological state is called paroxysmal nocturnal hemoglobinuria (PNH). Loss of protective proteins on the cell surface makes the red blood cells of PNH patients sensitive to complement-mediated lysis.
    Clone
    4A143-30
    Isotype
    IgG1
    Top Product
    Discover our top product CD55 Anticorps primaire
  • Indications d'application
    Optimal working dilution should be determined by the investigator.
    Procédure de l'essai
    • Take 100 μL peripheral blood anticoagulated by EDTA and add to the bottom of 5 mLtube,
    • Add 10 μL labeled antibody to the bottom of flow tube mixing with the whole blood, incubate for 20 minutes at room temperature away from light,
    • Add 2 ml1×RBC lysis buffer, incubate for 10 minutes away from light after mixing, dissolve red blood cells (recommended: RBC Lysing Solution 10×,Cat.: FXP001),
    • Sample tube is set to 1000 rpm centrifugation for 5 minutes, discard the supernatant,
    • Add 2 mLPBS wash buffer to resuspend the cells, then1000 rpm centrifugation for 5 minutes, discard the supernatant,
    • Add 0.5 mLPBS wash buffer to resuspend the cells and detect by flow cytometry (sample should be determined on the day on the machine and can also be added fixation overnight at 4 °C then measured).
    • [PBS wash buffer: PBS +1 % FBS +0.1 % NaN3, Cat.: FXP005]
    • [Cell fixation: 2 % formaldehyde solution]
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Phosphate-buffered solution, pH 7.4, containing and 0.2 % (w/v) BSA
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C
  • Antigène
    CD55 (Complement Decay-Accelerating Factor (CD55))
    Autre désignation
    CD55 (CD55 Produits)
    Synonymes
    anticorps CR, anticorps CROM, anticorps DAF, anticorps TC, anticorps Daf, anticorps Daf-GPI, anticorps Daf1, anticorps GPI-DAF, anticorps CD55 molecule (Cromer blood group), anticorps CD55 molecule, decay accelerating factor for complement, anticorps CD55, anticorps Cd55
    Pathways
    Système du Complément, Regulation of Leukocyte Mediated Immunity
Vous êtes ici:
Support technique